
- December 2026 Multiple Myeloma Guide for Pharmacists
Bringing Bispecifics Home: Practical Considerations for Outpatient and Community Integration in Relapsed/Refractory Multiple Myeloma
Key Takeaways
- Outpatient step-up dosing is now routine across diverse institutions, yet limited chair time, staffing, and infrastructure—rather than clinical reluctance—have become the primary access bottlenecks.
- Patient “readiness” depends heavily on caregiver reliability, proximity, literacy, comorbidities, and risk tolerance, prompting interest in psychosocial screening methods used in CAR T-cell and transplant programs.
Hear the key takeaways from thirteen pharmacists from different institutions on facilitating outpatient and community integration of bispecifics in multiple myeloma.
Introduction
T-cell engaging bispecific antibodies have become a routine part of care for relapsed/refractory multiple myeloma (RRMM), and their administration is moving out of inpatient care. Four agents are available: teclistamab, elranatamab, and linvoseltamab, which target B-cell maturation antigen (BCMA), and talquetamab, which targets GPRC5D. Each carries a risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), requires step-up dosing, and is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) program.1-8 Labeled observation after step-up doses ranges from 24 to 48 hours,5-8 which historically has meant multiday admissions.
Several forces are pushing these therapies toward outpatient and community settings. Inpatient beds are scarce, and academic referral queues for step-up dosing now stretch 3 to 4 weeks at some centers. Teclistamab plus daratumumab is now FDA approved after at least 1 prior line of therapy,5 which has expanded the eligible population.9 Real-world outpatient experience at academic and community sites10,11 and wider use of prophylactic tocilizumab have shown that outpatient step-up dosing can be done safely in select patients.4 Pharmacists lead the development of order sets, maintain REMS compliance, and educate patients and staff.
In August 2026, Pharmacy Times® convened 2 virtual roundtables; an East Coast group met on August 18 and a West Coast group on August 19. Both were moderated by Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, director of pharmacy, advanced therapeutics, at The University of Kansas Health System. Thirteen pharmacists from 13 institutions across 8 states took part; 77% were board certified in oncology pharmacy, and the group spanned academic medical centers, National Cancer Institute–designated cancer centers, and community-based health systems. Working through 2 patient cases, participants examined step-up dosing models, monitoring and escalation, academic-community handoffs, supportive care, and payer barriers. This paper summarizes those discussions, the practice gaps they revealed, and practical strategies pharmacists can use to close them.
Current Landscape of Outpatient Step-Up Dosing
Among these pharmacists’ institutions, outpatient step-up dosing is no longer experimental. In the pre-event survey (N = 12), every respondent’s organization administered step-up doses outside a full inpatient stay: 33% exclusively in the outpatient setting and 67% in a hybrid model. Two-thirds had supported more than 20 patients receiving myeloma bispecifics in the previous 6 months, and 92% had supported more than 10. No organization referred all step-up dosing elsewhere or admitted every patient.
Several academic centers treat outpatient as the default and admit only for social reasons, such as the lack of a caregiver. Others use institutional algorithms to choose the setting, and some admit every community referral until the first full dose is given. A community health system pharmacist said their practice referred all myeloma step-up dosing to a nearby academic center until the approval of tarlatamab for small cell lung cancer made referral impractical; staff training followed, and their practice now gives step-up doses at 1 central site before returning patients to its satellite clinics.
Experience has not removed the operational load (Figure 1). Two-thirds of respondents ranked institutional resources and infrastructure among their most difficult challenges, followed by staff, patient, and caregiver education (58%) and monitoring requirements (50%). Participants agreed that capacity, not willingness, now limits access. One academic pharmacist reported outpatient step-up slots booked 3 to 4 weeks out as myeloma, lymphoma, and lung cancer bispecific volumes grow. Approval of teclistamab plus daratumumab in earlier lines has added to that queue.
Key Discussion Themes
Outpatient Readiness Is Built, Not Assumed
Participants agreed that eligibility for outpatient step-up dosing depends as much on the patient’s support system as on the disease. Commonly cited criteria were a reliable caregiver, distance from the center, health literacy, performance status, comorbidities, and disease burden.11,12 One participant described a patient who, after fever counseling, took trimethoprim-sulfamethoxazole instead of pocket dexamethasone, a reminder that heavily pretreated patients can still misunderstand instructions. Selecting ideal candidates for outpatient administration is a key factor in ensuring a successful transition; one participant suggested borrowing validated psychosocial assessments from outpatient chimeric antigen receptor T-cell or transplant programs to assess patient readiness.
Distance limits ranged from 30 to 60 minutes. One center expanded its limit to 45 minutes, then returned to 30 after learning that ambulances take patients to the nearest hospital, which may not be prepared for CRS or ICANS. For new programs, an academic clinical pharmacy specialist advised, “It might not be a bad idea to pick your perfect ideal patients to get these processes started,” and loosening criteria as comfort grows. An oncology pharmacist added that “a community center doesn’t have to do their first time in an outpatient setting”; practices with an affiliated hospital can begin inpatient, where nurse and inpatient pharmacist education become the main work.
After-Hours Escalation Is the Constraint
CRS can emerge overnight or over a weekend, when community practices are least staffed. “Everyone wants to do it but then they run out of staff for, like, if there’s a 24-hour call or if they need someone overnight to answer a phone,” an academic pharmacist said of community partners. Sites schedule step-up doses so the highest-risk windows fall on weekdays (eg, Monday, Thursday, Monday). One community practice trains on-call nurses to route any call that begins “I’m a bispecific patient” straight to the on-call physician. Participants also stressed identifying a receiving hospital in advance, citing emergency department (ED) waits of several hours, and hospitalists unfamiliar with bispecifics. The moderator noted that a clinic able to manage febrile neutropenia already has the foundation of a CRS escalation plan.
Remote monitoring drew mixed reviews. One center pairs wearable devices with a 24-hour call center and now doses on any day of the week. Another, on its second vendor, found it “more anxiolytic for us than it was necessary for the program.” Participants agreed that data help only when someone owns them. Several sites have reduced home vital sign checks from every 4 hours to every 8 or 12 hours, and one lets patients log vitals through the electronic health record (EHR) patient portal.
The Handoff Has No Shared Playbook
Transitions between academic and community practices generated the most frustration. Return to community care ranged from after the first full dose to after a full cycle; some academic centers keep patients for a cycle to watch for cytopenias, settle infection prophylaxis, and offset inpatient step-up costs. “That question is a point of continuous confusion because we haven’t always necessarily spelled it out,” an oncology pharmacist said. Restep-up after dose holds is a recurring dispute, with community practices sending patients back to one academic center repeatedly despite its policy of resuming full doses. International Myeloma Working Group guidance suggests repeating step-up dosing only after interruptions longer than approximately 4 weeks.³ Grade 3 or higher infections affect approximately 1 in 4 patients receiving bispecifics, and in 1 retrospective study of BCMA-targeted bispecifics, immunoglobulin replacement has been associated with approximately 90% fewer grade 3 to 5 infections.13,14 Receiving practices must therefore secure immunoglobulin authorization and product, which “can take sometimes months in the worst-case scenarios.” Payer network rules can decide where step-up happens; one patient had to cross state lines to reach an in-network site.
Supportive Care Still Varies Site to Site
Supportive care practices differed widely (Table 1). Prophylactic tocilizumab divided the panel, as it divides published guidance3,12: Several sites give it before every outpatient start and absorb the cost when it is not covered, reasoning that 1 avoided admission pays for the drug. Others reserve it for select patients or do not use it. A pharmacy manager cautioned against complacency: “Just because you dropped your CRS from 70% to 10% doesn’t mean it’s nothing. You jack up your volumes a lot, that 10% is going to be pretty meaningful.” Biosimilar mandates add stocking work when a payer requires a tocilizumab product a site does not carry.
Pharmacist Practice Gaps
Four gaps emerged across both roundtables, each supported by survey data and participant experience (Figure 2). In each, pharmacists are doing the work site by site, without a shared standard.
Strategies for Pharmacists
Standardize early and build it into the EHR. Participants who expanded quickly wished they had standardized from the start. Sites that work smoothly build step-up dosing, CRS grading and treatment, and take-home medications into treatment plans so any pharmacist or nurse can follow them. Useful features include a “day 0” take-home medication release with nurse documentation of pickup and standing daily infusion appointments during step-up dosing, so a dose day can move without searching for chair time.
Write the handoff down. A shared agreement should define when a patient returns, which party secures immunoglobulin and anti-infectives, how dose holds are handled, and whom to call. Several participants weigh the receiving clinic’s capabilities when choosing an agent because product availability and authorization rules vary by site.
Prepare the ED and hospitalists. Because staff turnover erases onetime lectures, sites have shifted to on-demand triage guides in the health system’s intranet, wallet cards or medical bracelets naming the bispecific, and confirmation that local hospitals stock tocilizumab.11,12
Lead education across every discipline. The most successful programs had provider champions and weekly meetings with nursing, pharmacy, scheduling, and leadership, and they followed up to confirm each group was actually trained. Manufacturers can help with REMS enrollment and nursing education within label limits, and unbranded monitoring kits help sites that cannot distribute branded materials. Patient materials should be written at accessible reading levels and in patients’ preferred languages.
Address cost and coverage up front. Practical tactics included submitting tocilizumab authorization with the bispecific, securing administrative approval to write off uncovered prophylactic doses, stocking each payer’s preferred tocilizumab biosimilar, and using observation status for inpatient starts. Pharmacists should also check patients’ outpatient cost sharing, such as Medicare coinsurance, and the lodging and travel costs that onsite step-up dosing can impose.
Recommendations and Future Directions
The sessions moved participants: In the postevent survey (N = 12), all felt confident or very confident supporting safe outpatient administration. Yet half still expect staffing, infrastructure, or 24/7 coverage to be the greatest barrier, and the 2 regions asked for different tools to support them (Figure 3). East Coast respondents favored protocol tools, with 5 of 6 requesting step-up dosing order sets, while West Coast respondents favored transition and access support. Here are 3 recommendations to address the needs of both regions.
Convene regional academic–community cohorts. Handoff norms differed even among neighboring centers. Small cohorts that pair an academic center with the community practices it refers to could agree on handoff criteria, immunoglobulin and prophylaxis setup, and escalation contacts.
Build an unbranded implementation tool kit. The most requested resources were step-up dosing order sets (42%), ED training tools (42%), handoff checklists (33%), and unbranded implementation resources (33%). Packaged together with multilingual patient and caregiver materials, they would allow a community practice to start without building everything from scratch.
Prepare ED and hospital partners. Short, on-demand education for ED and hospitalist pharmacists and nurses on CRS and ICANS recognition, as well as tocilizumab use, would reach the teams that receive these patients after hours.
Participants also pointed to the next wave of questions: extending dosing intervals in responding patients to reduce infections and cytopenias, predictive models to identify who will develop CRS despite prophylaxis, and minimal residual disease–guided, time-limited therapy.
Conclusion
Outpatient step-up dosing of bispecific antibodies in RRMM can be delivered safely in select patients and is increasingly standard at experienced centers, but the systems that support it remain local and informal. After-hours escalation, undefined handoffs, variable supportive care, and unprepared EDs limit how far these therapies can travel from the academic center. Shared protocols, written handoff agreements, and regional collaboration can let pharmacists bring bispecifics safely home to patients’ own communities.
References
- Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. doi:10.1056/NEJMoa2203478
- Lee HC, Zonder JA, Dhodapkar MV, et al. Linvoseltamab in patients with relapsed/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses. Clin Lymphoma Myeloma Leuk. 2026;26(2):e201-e212.e8. doi:10.1016/j.clml.2025.11.004
- Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205-e216. doi:10.1016/S1470-2045(24)00043-3
- Kowalski A, Lykon J, Diamond B, et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Adv. 2025;9(19):4979-4986. doi:10.1182/bloodadvances.2025016911
- Tecvayli. Prescribing information. Johnson & Johnson; 2026. Accessed October 20, 2026. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf
- Elrexfio. Prescribing information. Pfizer; 2025. Accessed October 20, 2026. https://labeling.pfizer.com/ShowLabeling.aspx?id=19669
- Lynozyfic. Prescribing information. Regeneron; 2025. Accessed October 20, 2026. https://www.regeneron.com/downloads/lynozyfic_fpi.pdf
- Talvey. Prescribing information. Janssen Biotech; 2025. Accessed October 20, 2026. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TALVEY-pi.pdf
- Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2026;394(8):739-752. doi:10.1056/NEJMoa2514663
- Sandahl TB, Soefje SA, Fonseca R, et al. Real-world safety and health care resource utilization of teclistamab under an outpatient model for step-up dosing administration. JCO Oncol Pract. 2025;21(5):702-709. doi:10.1200/OP-24-00489
- Raff L, Wilson R, Murphy R, et al. Outpatient care model for teclistamab step-up dosing for the treatment of relapsed or refractory multiple myeloma at OneOncology: insights from a managed network of independent physician-owned community-based oncology practices. J Clin Pathways. 2025;11(6):16-20. doi:10.25270/jcp.2025.11.01
- Mateos MV, Zamagni E, Gentile M, et al. European recommendations for transitioning the care of patients with multiple myeloma treated with B-cell maturation antigen bispecific antibodies from academic hospitals to community-based centers and for outpatient step-up dosing. EJHaem. 2026;7(3):e70290. doi:10.1002/jha2.70290
- Reynolds G, Cliff ERS, Mohyuddin GR, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898-5903. doi:10.1182/bloodadvances.2023010539
- Lancman G, Parsa K, Kotlarz K, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4(6):440-451. doi:10.1158/2643-3230.BCD-23-0049
Related to this article

